Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
antigen receptor (CAR) T-cell candidate for metastatic colorectal cancer and other guanylyl cyclase-C (GCC)-expressing cancers. Lyell will receive the rights outside of Taiwan, Macau, Hong Kong and mainland China, and will commercialise, develop, research and manufacture the therapy. ICT will be eligible for a $40m upfront payment, Lyell common stock shares of 1.9 million and an additional equity and cash consideration, including a $30m clinical milestone. The company will also receive up to $675m in sales milestones and up to $115m in regulatory milestones. Further equity may be granted with achievement of future clinical and regulatory milestones. US Phase I clinical trial data reveal dose-dependent activity of LYL273 in 12 patients who received lymphodepleting chemotherapy followed by the candidate, achieving a 67% overall response rate and an 83% disease control rate. The product candidate, enhanced with cluster of differentiation 19 (CD19) CAR expression and controlled
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Lyell Immunopharma reports Q3 results [Seeking Alpha]Seeking Alpha
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 GlobeNewswire
- Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
LYEL
Analyst Actions
- 11/24/25 - HC Wainwright
LYEL
Sec Filings
- 12/5/25 - Form S-3
- 12/5/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- LYEL's page on the SEC website